H. Léna
About
H. Léna is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology.
According to data from OpenAlex, H. Léna has authored 65 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Pulmonary and Respiratory Medicine, 43 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in H. Léna's work include Lung Cancer Treatments and Mutations (42 papers), Lung Cancer Research Studies (18 papers) and Cancer Immunotherapy and Biomarkers (16 papers). H. Léna is often cited by papers focused on Lung Cancer Treatments and Mutations (42 papers), Lung Cancer Research Studies (18 papers) and Cancer Immunotherapy and Biomarkers (16 papers). H. Léna collaborates with scholars based in France, United States and Italy. H. Léna's co-authors include G. Robinet, Fabrice Barlési, D. Paillotin, H. Bérard, I. Monnet, P. Fournel, Élisabeth Quoix, P. Thomas, M. Pérol and R. Gervais and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.
In The Last Decade
H. Léna
61 papers receiving 1.4k citations
Peers
H. Léna
Tatsuro Fukuhara Japan
Satoru Kitazono Japan
Ethan Sokol United States
Raju Titus Chacko India
Marta Jimenez France
Nushmia Z. Khokhar United States
Anne Morosky United States
Alex Martínez‐Martí Spain
Monika Serke Germany
Citations per year, relative to H. Léna H. Léna (= 1×)
peers
Tatsuro Fukuhara
Countries citing papers authored by H. Léna
Since
Specialization
Citations
This map shows the geographic impact of H. Léna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Léna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Léna more than expected).
Fields of papers citing papers by H. Léna
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by H. Léna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Léna. The network helps show where H. Léna may publish in the future.
Co-authorship network of co-authors of H. Léna
This figure shows the co-authorship network connecting the top 25 collaborators of H. Léna. A scholar is included among the top collaborators of H. Léna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Léna. H. Léna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Levallet, Guénaëlle, Christian Créveuil, Solenn Brosseau, et al.. (2025). MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial. Translational Oncology. 61. 102520–102520.
2.
Godbert, B., Élisa Gobbini, M. Zysman, et al.. (2024). 1317P Real-world immunotherapy (IO) rechallenge outcomes with nivolumab (NIV) in advanced non-small cell lung cancer (aNSCLC) in France: LIST study interim results. Annals of Oncology. 35. S838–S839.
3.
Russo, Giuseppe Lo, H. Léna, Dariusz M. Kowalski, et al.. (2024). OA08.05 Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC: Results from Phase 3 CARMEN-LC03 Trial. Journal of Thoracic Oncology. 19(10). S25–S26.
4.
Cabart, Mathilde, Loı̈c Mourey, Sophie C. Schneider, et al.. (2024). Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME database. Journal of Geriatric Oncology. 15(7). 101819–101819.
5.
Léna, H., J. Cadranel, Nicolas Girard, et al.. (2023). 1404P Clinical characteristics and therapeutics sequences of KRAS G12C metastatic non-small cell lung cancer (mNCSLC) patients treated by sotorasib in the French pre-marketing authorization (MA) early access program (cohort temporary authorization of use, cATU). Annals of Oncology. 34. S803–S804.
6.
Ricordel, Charles, et al.. (2022). Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance. Frontiers in Oncology. 12. 853501–853501.
7.
Corre, R., et al.. (2020). Coeliac-Like Disease Is a Rare Immune-Related Complication Induced by Nivolumab in NSCLC. Journal of Thoracic Oncology. 15(8). e147–e148.
8.
Bennouna, Jaafar, Nicolas Girard, Clarisse Audigier-Valette, et al.. (2019). Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial. Clinical Lung Cancer. 21(1). e10–e14.
9.
Garassino, Marina Chiara, Byoung Chul Cho, Julien Mazières, et al.. (2018). P1.01-21 Safety of Durvalumab Retreatment in Advanced NSCLC Patients Who Progressed Following Initial Disease Control In ATLANTIC. Journal of Thoracic Oncology. 13(10). S467–S468.
10.
Dansin, Éric, Laurent Mhanna, Laurent Greillier, et al.. (2018). Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort. Journal of Thoracic Oncology. 13(11). 1762–1770.
11.
Garassino, Marina Chiara, Johan Vansteenkiste, Joo-Hang Kim, et al.. (2017). PL04a.03: Durvalumab in ≥3rd-Line Locally Advanced or Metastatic, EGFR/ALK Wild-Type NSCLC: Results from the Phase 2 ATLANTIC Study. Journal of Thoracic Oncology. 12(1). S10–S11.
12.
Guibert, Nicolas, Fabrice Barlési, R. Descourt, et al.. (2017). OA10.06 Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations (Biomarker IFCT Study). Journal of Thoracic Oncology. 12(1). S283–S283.
13.
Palmero, Ramón, Paolo Bidoli, Igor Bondarenko, et al.. (2017). Final clinical results from SUNRISE: A phase III, randomized, double-blind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/IV nonsquamous non-small cell lung cancer. Annals of Oncology. 28. v487–v487.
14.
Ferollà, Piero, Tim Meyer, Wasat Mansoor, et al.. (2016). Efficacy and safety of pasireotide LAR or everolimus alone, or in combination in patients with advanced carcinoids (NET) of the lung/thymus: Results from the randomized, phase 2 LUNA study. Annals of Oncology. 27. vi136–vi136.
15.
Léna, H., Naiyer A. Rizvi, Jennifer Moriatis Wolf, et al.. (2016). 137O: Nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profling analyses. Journal of Thoracic Oncology. 11(4). S115–S116.
16.
Zalcman, Gérard, Naiyer A. Rizvi, H. Léna, et al.. (2015). Phase 2 Study of Nivolumab (ANTI-PROGRAMMED DEATH-1 [PD-1]) in Patients (PTS) with Advanced, Refractory Squamous (SQ) Non-Small Cell Lung Cancer (NSCLC). Annals of Oncology. 26. i29–i29.
17.
Vansteenkiste, Johan, Fabrice Barlési, Cornelius F. Waller, et al.. (2015). Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO). Annals of Oncology. 26(8). 1734–1740.
18.
Ricordel, Charles, Alexandra Lespagnol, M. Kerjouan, et al.. (2014). EFGR-mutant lung adenocarcinoma and Li-Fraumeni syndrome: Report of two cases and review of the literature. Lung Cancer. 87(1). 80–84.
19.
Vergnenègre, A., Christophe Combescure, P. Fournel, et al.. (2006). Cost-minimization analysis of a phase III trial comparing concurrent versus sequential radiochemotherapy for locally advanced non-small-cell lung cancer (GFPC-GLOT 95–01). Annals of Oncology. 17(8). 1269–1274.
20.
Bombaron, P., R Riou, P. Fournel, et al.. (2002). Carboplatin—etoposide combination in small cell lung cancer patients older than 70 years: a phase II trial. Lung Cancer. 35(1). 1–7.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Tatsuro Fukuhara Breakdown of academic impact, for papers by Satoru Kitazono Breakdown of academic impact, for papers by Ethan Sokol Breakdown of academic impact, for papers by Raju Titus Chacko Breakdown of academic impact, for papers by Marta Jimenez Breakdown of academic impact, for papers by Nushmia Z. Khokhar Breakdown of academic impact, for papers by Anne Morosky Breakdown of academic impact, for papers by Alex Martínez‐Martí Breakdown of academic impact, for papers by Monika Serke